<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02508077</url>
  </required_header>
  <id_info>
    <org_study_id>15117</org_study_id>
    <secondary_id>NCI-2015-01241</secondary_id>
    <secondary_id>118713</secondary_id>
    <secondary_id>15117</secondary_id>
    <nct_id>NCT02508077</nct_id>
  </id_info>
  <brief_title>FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer</brief_title>
  <official_title>A Prospective Study of FOLFIRI Plus Panitumumab in Extended RAS Wild Type and BRAF Wild Type Metastatic Colorectal Cancer With Acquired Resistance to Prior Cetuximab (or Panitumumab) Plus Irinotecan-Based Therapy and Who Failed at Least One Subsequent Non-anti-EGFR Containing Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well fluorouracil, leucovorin calcium, and irinotecan&#xD;
      hydrochloride (FOLFIRI) together with panitumumab work in treating patients with colorectal&#xD;
      cancer that expresses the RAS and B-Raf proto-oncogene, serine/threonine kinase (BRAF)&#xD;
      wild-type genes, has spread from the original site of growth to another part of the body&#xD;
      (metastatic), resists the effects of treatment with prior cetuximab (or panitumumab) plus&#xD;
      irinotecan hydrochloride-based therapy, and who have failed at least one subsequent&#xD;
      non-anti-epidermal growth factor receptor (EGFR) containing treatment regimen. Drugs used in&#xD;
      chemotherapy, such as fluorouracil, leucovorin calcium, and irinotecan hydrochloride, work in&#xD;
      different ways to stop the growth of tumor cells, either by killing the cells, by stopping&#xD;
      them from dividing, or by stopping them from spreading. Giving more than one drug&#xD;
      (combination chemotherapy) may kill more tumor cells. Monoclonal antibodies, such as&#xD;
      panitumumab, may block tumor growth in different ways by targeting certain cells. Giving&#xD;
      FOLFIRI together with panitumumab may be an effective treatment for colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Estimate the response rate (RR) and progression-free survival (PFS) with FOLFIRI +&#xD;
      panitumumab in patients with acquired resistance to panitumumab (or cetuximab) + irinotecan&#xD;
      (irinotecan hydrochloride)-based therapy after a documented clinical response or prolonged&#xD;
      PFS and following progression on a subsequent non-anti-EGFR containing regimen in extended&#xD;
      RAS wild-type and BRAF wild-type patients.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Estimate the overall survival (OS) in the re-challenge populations.&#xD;
&#xD;
      II. Describe the safety of re-challenge in this population.&#xD;
&#xD;
      III. Investigate the impact of PFS, RR on prior anti-EGFR + irinotecan-based exposure on the&#xD;
      response and PFS on the current study.&#xD;
&#xD;
      TERTIARY OBJECTIVES:&#xD;
&#xD;
      I. Collect serial plasma samples to investigate the incidence of RAS and BRAF mutation in&#xD;
      circulating free deoxyribonucleic acid (DNA) at baseline, every 2 months, and at the time to&#xD;
      progression (and following progression when feasible).&#xD;
&#xD;
      II. Collect serial plasma samples for future biomarker exploration, including the potential&#xD;
      investigation of micro-ribonucleic acid (RNA).&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive panitumumab intravenously (IV) over 30-90 minutes, irinotecan hydrochloride&#xD;
      IV over 90 minutes, leucovorin calcium orally (PO), and fluorouracil IV over 46 hours on day&#xD;
      1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 30 days and then every 3&#xD;
      months thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor Accrual&#xD;
  </why_stopped>
  <start_date type="Actual">February 16, 2016</start_date>
  <completion_date type="Actual">September 13, 2017</completion_date>
  <primary_completion_date type="Actual">September 13, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>4-month Progression-free Survival (PFS) Rate</measure>
    <time_frame>At 4 months</time_frame>
    <description>PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. Will be estimated using the product-limit method of Kaplan and Meier. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum on study (including baseline sum), or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Recurrent Colorectal Carcinoma</condition>
  <condition>Stage IVA Colorectal Cancer</condition>
  <condition>Stage IVB Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (panitumumab and FOLFIRI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive panitumumab IV over 30-90 minutes, irinotecan hydrochloride IV over 90 minutes, leucovorin calcium PO, and fluorouracil IV over 46 hours on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (panitumumab and FOLFIRI)</arm_group_label>
    <other_name>5-Fluoro-2,4(1H, 3H)-pyrimidinedione</other_name>
    <other_name>5-Fluorouracil</other_name>
    <other_name>5-Fluracil</other_name>
    <other_name>5-FU</other_name>
    <other_name>AccuSite</other_name>
    <other_name>Actino-Hermal</other_name>
    <other_name>Adrucil</other_name>
    <other_name>Arumel</other_name>
    <other_name>Cytosafe</other_name>
    <other_name>Efudex</other_name>
    <other_name>Efurix</other_name>
    <other_name>Fiverocil</other_name>
    <other_name>Fluoro Uracil</other_name>
    <other_name>Fluoroplex</other_name>
    <other_name>Fluouracil</other_name>
    <other_name>Flurablastin</other_name>
    <other_name>Fluracedyl</other_name>
    <other_name>Fluracil</other_name>
    <other_name>Fluril</other_name>
    <other_name>Fluroblastin</other_name>
    <other_name>Flurox</other_name>
    <other_name>Ribofluor</other_name>
    <other_name>Ro 2-9757</other_name>
    <other_name>Ro-2-9757</other_name>
    <other_name>Timazin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (panitumumab and FOLFIRI)</arm_group_label>
    <other_name>Campto</other_name>
    <other_name>Camptosar</other_name>
    <other_name>Camptothecin 11</other_name>
    <other_name>Camptothecin-11</other_name>
    <other_name>CPT 11</other_name>
    <other_name>CPT-11</other_name>
    <other_name>U-101440E</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (panitumumab and FOLFIRI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin Calcium</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (panitumumab and FOLFIRI)</arm_group_label>
    <other_name>Adinepar</other_name>
    <other_name>Calcifolin</other_name>
    <other_name>Calcium (6S)-Folinate</other_name>
    <other_name>Calcium Folinate</other_name>
    <other_name>Calcium Leucovorin</other_name>
    <other_name>Calfolex</other_name>
    <other_name>Calinat</other_name>
    <other_name>Cehafolin</other_name>
    <other_name>Citofolin</other_name>
    <other_name>Citrec</other_name>
    <other_name>Citrovorum Factor</other_name>
    <other_name>Cromatonbic Folinico</other_name>
    <other_name>Dalisol</other_name>
    <other_name>Disintox</other_name>
    <other_name>Divical</other_name>
    <other_name>Ecofol</other_name>
    <other_name>Emovis</other_name>
    <other_name>Factor, Citrovorum</other_name>
    <other_name>Flynoken A</other_name>
    <other_name>Folaren</other_name>
    <other_name>Folaxin</other_name>
    <other_name>FOLI-cell</other_name>
    <other_name>Foliben</other_name>
    <other_name>Folidan</other_name>
    <other_name>Folidar</other_name>
    <other_name>Folinac</other_name>
    <other_name>Folinate Calcium</other_name>
    <other_name>folinic acid</other_name>
    <other_name>Folinic Acid Calcium Salt Pentahydrate</other_name>
    <other_name>Folinoral</other_name>
    <other_name>Folinvit</other_name>
    <other_name>Foliplus</other_name>
    <other_name>Folix</other_name>
    <other_name>Imo</other_name>
    <other_name>Lederfolat</other_name>
    <other_name>Lederfolin</other_name>
    <other_name>Leucosar</other_name>
    <other_name>leucovorin</other_name>
    <other_name>Rescufolin</other_name>
    <other_name>Rescuvolin</other_name>
    <other_name>Tonofolin</other_name>
    <other_name>Wellcovorin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Panitumumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (panitumumab and FOLFIRI)</arm_group_label>
    <other_name>ABX-EGF</other_name>
    <other_name>ABX-EGF Monoclonal Antibody</other_name>
    <other_name>ABX-EGF, Clone E7.6.3</other_name>
    <other_name>MoAb ABX-EGF</other_name>
    <other_name>Monoclonal Antibody ABX-EGF</other_name>
    <other_name>Vectibix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant must have the ability to understand and the willingness to sign a written&#xD;
             informed consent document&#xD;
&#xD;
          -  Participant must be willing to comply with study and/or follow-up procedures&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2&#xD;
&#xD;
          -  Life expectancy of 3 &gt;= months&#xD;
&#xD;
          -  Histologically confirmed colon or rectal cancer with metastatic disease&#xD;
&#xD;
          -  Extended RAS and BRAF wild type status documented on archival tumor tissue or on fresh&#xD;
             biopsy if no archival tissue present&#xD;
&#xD;
          -  Measurable disease defined by at least 1 lesion &gt;= 1 cm&#xD;
&#xD;
          -  Documented objective response or stable disease lasting for 6 months or more to last&#xD;
             prior anti-EGFR (cetuximab or panitumumab) in combination with irinotecan or FOLFIRI&#xD;
&#xD;
          -  Progression within 6 weeks following their last dose of anti-EGFR therapy&#xD;
&#xD;
          -  Treatment with a non-EGFR targeting regimen following progression on anti-EGFR plus&#xD;
             irinotecan-based therapy&#xD;
&#xD;
          -  At least 4 months from prior anti-EGFR therapy prior to start of study treatment&#xD;
&#xD;
          -  At least three weeks from any non-anti-EGFR therapy prior to start of study treatment;&#xD;
             any number of prior therapies is permitted&#xD;
&#xD;
          -  Adequate recovery in the investigators opinion from any clinically significant&#xD;
             toxicity from prior therapy&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1.5 x 10^9/L&#xD;
&#xD;
          -  Hemoglobin (Hgb) &gt;= 9 g/dL without transfusions&#xD;
&#xD;
          -  Platelets (PLT) &gt;= 100 x 10^9/L without transfusions&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])&#xD;
             and/or alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])&#xD;
             =&lt; 2.5 x upper limit of normal (ULN); patient with liver metastases =&lt; 5 x ULN&#xD;
&#xD;
          -  Total bilirubin =&lt; ULN&#xD;
&#xD;
          -  Creatinine =&lt; 1.5 mg/dL&#xD;
&#xD;
          -  Magnesium &gt;= 1.2mg/dL or 0.5 mmol/L&#xD;
&#xD;
          -  Negative serum beta-human chorionic gonadotropin (HCG) test (female patient of&#xD;
             childbearing potential only), to be performed locally within the screening period&#xD;
&#xD;
          -  Agreement by females of childbearing potential and sexually active males to use an&#xD;
             effective method of contraception (hormonal or barrier method of birth control or&#xD;
             abstinence) prior to study entry and for three months following duration of study&#xD;
             participation; should a woman become pregnant or suspect that she is pregnant while&#xD;
             participating on the trial, she should inform her treating physician immediately&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of severe anti-EGFR toxicity requiring drug discontinuation or&#xD;
             dose-modification within the first 4 months of prior anti-EGFR therapy&#xD;
&#xD;
          -  History of intolerance to irinotecan at dose-intensity of 125 mg/m^2/2 weeks or lower&#xD;
&#xD;
          -  History of intolerance to 5-FU at dose-intensity of 1800 mg/m^2/2 weeks or lower&#xD;
&#xD;
          -  Current use (or planned use during the treatment period) of other investigational&#xD;
             agents, or biological, chemotherapy, radiation or other anti-tumor therapy&#xD;
&#xD;
          -  Co-medication that may interfere with study results; e.g. immuno-suppressive agents&#xD;
             other than corticosteroids, such as systemic cyclosporine and tacrolimus&#xD;
&#xD;
          -  No St John's wort supplement or other herbal supplementation is allowed while on&#xD;
             trial; patients are not to take grapefruit juice during study treatment&#xD;
&#xD;
          -  Use of drugs known to inhibit UDP glycosyltransferase 1 family, polypeptide A1 gene&#xD;
             (UGT1A1), such as Atazanavir, Gemfibrozil, Indinavir, or Ketoconazole while on study&#xD;
             treatment; (patients using these drugs must not take these drugs on the day study&#xD;
             treatment begins and for the duration of study treatment)&#xD;
&#xD;
          -  Planned use of strong cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4)&#xD;
             inhibitors or CYP3A4 inducers while on study treatment unless deemed clinically&#xD;
             necessary with no reasonable alternatives and with expressed permission from the&#xD;
             principal investigator&#xD;
&#xD;
          -  If on anticoagulation, participant must be on stable therapeutic dose prior to&#xD;
             enrollment&#xD;
&#xD;
          -  Impairment of gastrointestinal function or gastrointestinal disease (e.g., active&#xD;
             ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome,&#xD;
             extensive small bowel resection)&#xD;
&#xD;
          -  Major surgery =&lt; 3 weeks prior to starting study drug or who have not recovered from&#xD;
             side effects of such procedure&#xD;
&#xD;
          -  Unstable pulmonary embolism, deep vein thrombosis, or other significant&#xD;
             arterial/venous thromboembolic event =&lt; 30 days before enrollment&#xD;
&#xD;
          -  Clinically significant cardiovascular disease (including myocardial infarction,&#xD;
             unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac&#xD;
             arrhythmia) =&lt; 6 months prior to enrollment&#xD;
&#xD;
          -  History of interstitial lung disease (ILD) eg, interstitial pneumonitis, pulmonary&#xD;
             fibrosis or evidence of ILD on baseline chest computed tomography (CT) or magnetic&#xD;
             resonance imaging (MRI)&#xD;
&#xD;
          -  Other active malignancies except cervical carcinomas in situ or clinically&#xD;
             insignificant non-melanoma skin cancers&#xD;
&#xD;
          -  Clinically significant uncontrolled illness or active infections&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to irinotecan, 5-FU, leucovorin or any of the products to be administered&#xD;
             during dosing&#xD;
&#xD;
          -  Pregnant women and women who are lactating; breastfeeding should be discontinued if&#xD;
             the mother is enrolled on this study&#xD;
&#xD;
          -  Any other condition that would, in the Investigator's judgment, contraindicate the&#xD;
             patient's participation in the clinical study due to safety concerns or compliance&#xD;
             with clinical study procedures, e.g., infection/inflammation, intestinal obstruction,&#xD;
             unable to swallow medication, social/psychological issues, etc&#xD;
&#xD;
          -  Prospective participants who, in the opinion of the investigator, may not be able to&#xD;
             comply with all study procedures (including compliance issues related to&#xD;
             feasibility/logistics)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marwan Fakih</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope Antelope Valley</name>
      <address>
        <city>Lancaster</city>
        <state>California</state>
        <zip>93534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope Rancho Cucamonga</name>
      <address>
        <city>Rancho Cucamonga</city>
        <state>California</state>
        <zip>91730</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Pasadena Cancer Center</name>
      <address>
        <city>South Pasadena</city>
        <state>California</state>
        <zip>91030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 22, 2015</study_first_submitted>
  <study_first_submitted_qc>July 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2015</study_first_posted>
  <results_first_submitted>July 20, 2018</results_first_submitted>
  <results_first_submitted_qc>July 20, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 16, 2018</results_first_posted>
  <last_update_submitted>July 20, 2018</last_update_submitted>
  <last_update_submitted_qc>July 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Panitumumab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 7, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT02508077/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Panitumumab and FOLFIRI)</title>
          <description>Patients receive 6mg/kg panitumumab IV over 30-90 minutes, 180mg/m2 irinotecan hydrochloride IV over 90 minutes, 400mg/m2 leucovorin calcium PO, and 2400mg/m2 fluorouracil IV over 46 hours on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
Fluorouracil: Given IV&#xD;
Irinotecan Hydrochloride: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Leucovorin Calcium: Given PO&#xD;
Panitumumab: Given IV</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Panitumumab and FOLFIRI)</title>
          <description>Patients receive 6mg/kg panitumumab IV over 30-90 minutes, 180mg/m2 irinotecan hydrochloride IV over 90 minutes, 400mg/m2 leucovorin calcium PO, and 2400mg/m2 fluorouracil IV over 46 hours on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
Fluorouracil: Given IV&#xD;
Irinotecan Hydrochloride: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Leucovorin Calcium: Given PO&#xD;
Panitumumab: Given IV</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" lower_limit="57" upper_limit="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>4-month Progression-free Survival (PFS) Rate</title>
        <description>PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. Will be estimated using the product-limit method of Kaplan and Meier. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum on study (including baseline sum), or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
        <time_frame>At 4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Panitumumab and FOLFIRI)</title>
            <description>Patients receive 6mg/kg panitumumab IV over 30-90 minutes, 180mg/m2 irinotecan hydrochloride IV over 90 minutes, 400mg/m2 leucovorin calcium PO, and 2400mg/m2 fluorouracil IV over 46 hours on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
Fluorouracil: Given IV&#xD;
Irinotecan Hydrochloride: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Leucovorin Calcium: Given PO&#xD;
Panitumumab: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>4-month Progression-free Survival (PFS) Rate</title>
          <description>PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. Will be estimated using the product-limit method of Kaplan and Meier. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum on study (including baseline sum), or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events occurred over a period of 12 weeks.</time_frame>
      <desc>&quot;Other Adverse Events&quot; include all events that were not severe adverse events regardless of grade or relation to treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Panitumumab and FOLFIRI)</title>
          <description>Patients receive 6mg/kg panitumumab IV over 30-90 minutes, 180mg/m2 irinotecan hydrochloride IV over 90 minutes, 400mg/m2 leucovorin calcium PO, and 2400mg/m2 fluorouracil IV over 46 hours on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
Fluorouracil: Given IV&#xD;
Irinotecan Hydrochloride: Given IV&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Leucovorin Calcium: Given PO&#xD;
Panitumumab: Given IV</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>blood anion gap decreased.</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypermagnesemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was terminated early due to poor accrual.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Paul Frankel, Ph.D.</name_or_title>
      <organization>City of Hope</organization>
      <phone>626-218-5265</phone>
      <email>pfrankel@coh.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

